These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 22811580)

  • 21. Drug sensitivity and resistance testing identifies PLK1 inhibitors and gemcitabine as potent drugs for malignant peripheral nerve sheath tumors.
    Kolberg M; Bruun J; Murumägi A; Mpindi JP; Bergsland CH; Høland M; Eilertsen IA; Danielsen SA; Kallioniemi O; Lothe RA
    Mol Oncol; 2017 Sep; 11(9):1156-1171. PubMed ID: 28556483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1.
    Barkan B; Starinsky S; Friedman E; Stein R; Kloog Y
    Clin Cancer Res; 2006 Sep; 12(18):5533-42. PubMed ID: 17000690
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Initial testing of the aurora kinase A inhibitor MLN8237 by the Pediatric Preclinical Testing Program (PPTP).
    Maris JM; Morton CL; Gorlick R; Kolb EA; Lock R; Carol H; Keir ST; Reynolds CP; Kang MH; Wu J; Smith MA; Houghton PJ
    Pediatr Blood Cancer; 2010 Jul; 55(1):26-34. PubMed ID: 20108338
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Malignant peripheral nerve sheath tumors with high and low Ras-GTP are permissive for oncolytic herpes simplex virus mutants.
    Mahller YY; Rangwala F; Ratner N; Cripe TP
    Pediatr Blood Cancer; 2006 Jun; 46(7):745-54. PubMed ID: 16124003
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Schwann cell lines derived from malignant peripheral nerve sheath tumors respond abnormally to platelet-derived growth factor-BB.
    Dang I; DeVries GH
    J Neurosci Res; 2005 Feb; 79(3):318-28. PubMed ID: 15602756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Polo-like kinase 1 as a therapeutic target for malignant peripheral nerve sheath tumors (MPNST) and schwannomas.
    Guo J; Chaney KE; Choi K; Witek G; Patel AV; Xie H; Lin D; Whig K; Xiong Y; Schultz DC; Ratner N; Field J
    Am J Cancer Res; 2020; 10(3):856-869. PubMed ID: 32266095
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aurora A inhibitor (MLN8237) plus vincristine plus rituximab is synthetic lethal and a potential curative therapy in aggressive B-cell non-Hodgkin lymphoma.
    Mahadevan D; Stejskal A; Cooke LS; Manziello A; Morales C; Persky DO; Fisher RI; Miller TP; Qi W
    Clin Cancer Res; 2012 Apr; 18(8):2210-9. PubMed ID: 22374334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.
    Görgün G; Calabrese E; Hideshima T; Ecsedy J; Perrone G; Mani M; Ikeda H; Bianchi G; Hu Y; Cirstea D; Santo L; Tai YT; Nahar S; Zheng M; Bandi M; Carrasco RD; Raje N; Munshi N; Richardson P; Anderson KC
    Blood; 2010 Jun; 115(25):5202-13. PubMed ID: 20382844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of neurofibromin in N-Ras mediated AP-1 regulation in malignant peripheral nerve sheath tumors.
    Kraniak JM; Sun D; Mattingly RR; Reiners JJ; Tainsky MA
    Mol Cell Biochem; 2010 Nov; 344(1-2):267-76. PubMed ID: 20680410
    [TBL] [Abstract][Full Text] [Related]  

  • 30. STING activation reprograms the microenvironment to sensitize NF1-related malignant peripheral nerve sheath tumors for immunotherapy.
    Somatilaka BN; Madana L; Sadek A; Chen Z; Chandrasekaran S; McKay RM; Le LQ
    J Clin Invest; 2024 Mar; 134(10):. PubMed ID: 38502231
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.
    Kazmi SJ; Byer SJ; Eckert JM; Turk AN; Huijbregts RP; Brossier NM; Grizzle WE; Mikhail FM; Roth KA; Carroll SL
    Am J Pathol; 2013 Mar; 182(3):646-67. PubMed ID: 23321323
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined Inhibition of SHP2 and MEK Is Effective in Models of NF1-Deficient Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Allen AN; Tomar T; Pijnenburg D; Yao Z; Rodriguez FJ; Pratilas CA
    Cancer Res; 2020 Dec; 80(23):5367-5379. PubMed ID: 33032988
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic Profiling in Patients With Malignant Peripheral Nerve Sheath Tumors Reveals Multiple Pathways With Targetable Mutations.
    Kaplan HG; Rostad S; Ross JS; Ali SM; Millis SZ
    J Natl Compr Canc Netw; 2018 Aug; 16(8):967-974. PubMed ID: 30099373
    [No Abstract]   [Full Text] [Related]  

  • 34. The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells.
    Fischer-Huchzermeyer S; Dombrowski A; Hagel C; Mautner VF; Schittenhelm J; Harder A
    Am J Pathol; 2017 Jul; 187(7):1623-1632. PubMed ID: 28502478
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LPAR1 and aberrantly expressed LPAR3 differentially promote the migration and proliferation of malignant peripheral nerve sheath tumor cells.
    Doutt SW; Longo JF; Carroll SL
    Glia; 2023 Mar; 71(3):742-757. PubMed ID: 36416236
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microarray-based copy number analysis of neurofibromatosis type-1 (NF1)-associated malignant peripheral nerve sheath tumors reveals a role for Rho-GTPase pathway genes in NF1 tumorigenesis.
    Upadhyaya M; Spurlock G; Thomas L; Thomas NS; Richards M; Mautner VF; Cooper DN; Guha A; Yan J
    Hum Mutat; 2012 Apr; 33(4):763-76. PubMed ID: 22331697
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sensitivity of malignant peripheral nerve sheath tumor cells to TRAIL is augmented by loss of NF1 through modulation of MYC/MAD and is potentiated by curcumin through induction of ROS.
    Reuss DE; Mucha J; Hagenlocher C; Ehemann V; Kluwe L; Mautner V; von Deimling A
    PLoS One; 2013; 8(2):e57152. PubMed ID: 23437333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activation of Receptor Tyrosine Kinases Mediates Acquired Resistance to MEK Inhibition in Malignant Peripheral Nerve Sheath Tumors.
    Wang J; Pollard K; Calizo A; Pratilas CA
    Cancer Res; 2021 Feb; 81(3):747-762. PubMed ID: 33203698
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Eyes Absent Homolog 4 expression induces malignant peripheral nerve sheath tumor necrosis.
    Miller SJ; Lan ZD; Hardiman A; Wu J; Kordich JJ; Patmore DM; Hegde RS; Cripe TP; Cancelas JA; Collins MH; Ratner N
    Oncogene; 2010 Jan; 29(3):368-79. PubMed ID: 19901965
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The combination of alisertib, an investigational Aurora kinase A inhibitor, and docetaxel promotes cell death and reduces tumor growth in preclinical cell models of upper gastrointestinal adenocarcinomas.
    Sehdev V; Katsha A; Ecsedy J; Zaika A; Belkhiri A; El-Rifai W
    Cancer; 2013 Feb; 119(4):904-14. PubMed ID: 22972611
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.